- Home
- IMAB
IMAB
I-MAB
as 10-27-2025 9:35am EST
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
| Founded: | 2014 | Country: | United States |
| Employees: | 32 | City: | N/A |
| Market Cap: | 486.4M | IPO Year: | 2020 |
| Target Price: | $7.50 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.59 - $6.79 | Next Earning Date: | 11-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest I-MAB News
IMAB Breaking Stock News: Dive into IMAB Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025
PR Newswire
11 days ago
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
MT Newswires
13 days ago
Asian Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading
GlobeNewswire
14 days ago
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Simply Wall St.
17 days ago
I-Mab's (NASDAQ:IMAB) market cap surged US$52m last week, individual investors who have a lot riding on the company were rewarded
Zacks
17 days ago
I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should Know
Zacks
21 days ago
What Makes IMab (IMAB) a New Buy Stock
GlobeNewswire
3 months ago
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
Compare IMAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMAB I-MAB - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.